alexa A New Recombinant BCG Vaccine Induces Specific Th17 And Th1 Effector Cells With Higher Protective Efficacy Against Tuberculosis
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th International Conference on Vaccines & Vaccination
September 24-26, 2014 Valencia Convention Centre, Spain

Ana Paula Junqueira-Kipnis, Adeliane C da Costa, Abadio O C Junior, Fabio M Oliveira, Sarah V Nogueira, Joseane D Rosa, Danilo P Resende and Andre Kipnis
Accepted Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.022
T uberculosis is an infectious disease caused by Mycobacterium tuberculosis (Mtb) that is a major public health problem. The vaccine used in TB prevention is the Mycobacterium bovis- BCG that presents a variable efficacy in protecting against pulmonary TB. Thus, the development of new vaccines with superior BCG protection efficacy has been the target of several studies. Here we constructed a new recombinant BCG vaccine expressing a fusion protein composed of immune epitopes from Ag85C, MPT51 and HspX (CMX) and evaluated its immunogenicity and protection in a murine model of infection. The stability of the vaccine in vivo was maintained up to 20 days post vaccination. rBCG-CMX is highly phagocytized by peritoneal macrophages and induces NO production. After mouse vaccination, this vaccine induced specific immune response to the fusion protein in cells from lungs and spleens. Vaccinated mice presented higher amounts of Th1, Th17, and polyfunctional specific Th cells. The vaccine reduced almost half a log of the lung bacterial load when compared to BCG vaccinated animals. This study shows a new promising vaccine for tuberculosis posing a candidate for clinical trials
Ana Paula Junqueira-Kipnis has completed her PhD at the age of 30 years from Universidade de S?o Paulo and Postdoctoral studies from Colorado State University, Fort Collins, CO and Albert Einstein College of Medicine, New York, NY. She is the Head of Immunopathology Laboratories for infectious Diseases at Federal University of Goias, Brazil. She has received a prize for innovation in public health by Sanofis Laboratory in 2012 for designing a new vaccine for TB. She has published more than 40 papers in reputed journals and serving as a reviewer board member of several reputed journals.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version